Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment

AIMS: Olaparib, a potent oral poly(ADP‐ribose) polymerase inhibitor, is partially hepatically cleared. We investigated the pharmacokinetics (PK) and safety of olaparib in patients with mild or moderate hepatic impairment to provide dosing recommendations. METHODS: This Phase I open‐label study asses...

詳細記述

保存先:
書誌詳細
出版年:Br J Clin Pharmacol
主要な著者: Rolfo, Christian, Isambert, Nicolas, Italiano, Antoine, Molife, L. Rhoda, Schellens, Jan H.M., Blay, Jean‐Yves, Decaens, Thomas, Kristeleit, Rebecca, Rosmorduc, Olivier, Demlova, Regina, Lee, Myung‐Ah, Ravaud, Alain, Kopeckova, Katerina, Learoyd, Maria, Bannister, Wendy, Locker, Gershon, de Vos‐Geelen, Judith
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley and Sons Inc. 2020
主題:
Original Articles
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7444797/
https://ncbi.nlm.nih.gov/pubmed/32227355
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14283
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料